November 16th, 2026FDA Updates Aficamten Label With MAPLE-HCM Data in Obstructive HCMAficamten's label now includes MAPLE-HCM data, in which aficamten monotherapy improved peak VO2 by 2.3 mL/kg/min more than metoprolol at 24 weeks.Read more
November 16th, 2026FDA Approves Dexmedetomidine for At-Home Schizophrenia, Bipolar AgitationDexmedetomidine sublingual film is the first FDA-approved at-home option for acute agitation, based on the phase 3 SERENITY at-home trial.Read more
November 14th, 2026FDA Approves Obinutuzumab (Gazyva) for Primary Membranous NephropathyApproval of obinutuzumab for adults with PMN follows MAJESTY, where 37% vs 6% achieved complete remission at week 104 vs tacrolimus.Read more
November 13th, 2026Omalizumab, Remibrutinib Show Similar Early CSU Gains in Indirect AnalysisA post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.Read more
November 13th, 2026Etavopivat Submitted to FDA After 27% VOC Reduction in Phase 3 SCD TrialHIBISCUS showed a 48.7% vs 7.2% hemoglobin response at week 24, with an FDA decision expected in 2027.Read more
November 13th, 2026ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand EczemaExperts outline when to stop cycling topical steroids in chronic hand eczema and where topical delgocitinib now fits.Read more
November 12th, 2026Q&A: Healthy Skin Month—What Clinicians Should Watch in Skin Cancer CareLeigh Ann Pansch, MSN, FNP-BC, DCNP, discusses year-round photoprotection, missed skin cancer detection, and overlooked patients for Healthy Skin Month.Read more
November 12th, 2026Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU ControlPost hoc analyses at ACAAI 2026 show 41.7% of patients-maintained CSU control and quality of life 16 weeks after stopping omalizumab.Read more